LS Investment Advisors LLC Purchases 570 Shares of Kenvue Inc. (NYSE:KVUE)

LS Investment Advisors LLC grew its position in Kenvue Inc. (NYSE:KVUE) by 1.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 51,745 shares of the company’s stock after buying an additional 570 shares during the period. LS Investment Advisors LLC’s holdings in Kenvue were worth $1,197,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after buying an additional 25,238,112 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kenvue by 12.0% during the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after acquiring an additional 17,908,497 shares during the period. Van ECK Associates Corp boosted its stake in Kenvue by 110.9% in the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock worth $372,880,000 after purchasing an additional 10,783,258 shares during the period. Clearbridge Investments LLC increased its holdings in Kenvue by 16,051.1% during the 1st quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock worth $210,600,000 after purchasing an additional 9,752,836 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Kenvue by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock valued at $789,813,000 after purchasing an additional 7,546,362 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 2.1 %

KVUE opened at $22.97 on Friday. The stock’s fifty day simple moving average is $22.61 and its 200 day simple moving average is $20.50. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.57. The stock has a market cap of $43.99 billion, a PE ratio of 39.60, a price-to-earnings-growth ratio of 3.01 and a beta of 1.36. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 earnings per share. As a group, research analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.57%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 141.38%.

Analysts Set New Price Targets

Several research firms have recently weighed in on KVUE. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.